| 000 | 01798 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250515114708.0 | ||
| 264 | 0 | _c20081222 | |
| 008 | 200812s 0 0 eng d | ||
| 022 | _a1432-0843 | ||
| 024 | 7 |
_a10.1007/s00280-008-0730-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMenon-Andersen, Divya | |
| 245 | 0 | 0 |
_aPopulation pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. _h[electronic resource] |
| 260 |
_bCancer chemotherapy and pharmacology _cJan 2009 |
||
| 300 |
_a229-38 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 |
_aAging _xblood |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xblood |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGastrointestinal Stromal Tumors _xblood |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImatinib Mesylate |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aModels, Biological |
| 650 | 0 | 4 | _aMultivariate Analysis |
| 650 | 0 | 4 |
_aPiperazines _xblood |
| 650 | 0 | 4 |
_aPyrimidines _xblood |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aMondick, John T | |
| 700 | 1 | _aJayaraman, Bhuvana | |
| 700 | 1 | _aThompson, Patrick A | |
| 700 | 1 | _aBlaney, Susan M | |
| 700 | 1 | _aBernstein, Mark | |
| 700 | 1 | _aBond, Mason | |
| 700 | 1 | _aChampagne, Martin | |
| 700 | 1 | _aFossler, Michael J | |
| 700 | 1 | _aBarrett, Jeffrey S | |
| 773 | 0 |
_tCancer chemotherapy and pharmacology _gvol. 63 _gno. 2 _gp. 229-38 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00280-008-0730-x _zAvailable from publisher's website |
| 999 |
_c17897281 _d17897281 |
||